B
BioLineRx Ltd D
D
BLRX
3.64000
USD
-0.26
(-6.67%)
مغلق
حجم التداول
249
الربح لكل سهم
-13
العائد الربحي
-
P/E
-1
حجم السوق
13,544,451
الأخبار المقالات
العنوان: BioLineRx Ltd
القطاع: Healthcare
الصناعة: Biotechnology
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.